Genovese MC, et al. - Authors evaluated 2-year safety, efficacy and radiographic outcomes of sarilumab in adults with rheumatoid arthritis (RA) and inadequate response to MTX (MTX-IR). Findings suggested consistent safety of sarilumab through year 2 with IL-6 receptor blockade. Irrespective of initial treatment and radiographic progression stabilized, clinical response was similar. Best radiographic outcomes were seen in the patients initiated on sarilumab 200 mg q2w. It was determined that dose reduction allowed most patients to continue with the study.